Preview

Артериальная гипертензия

Расширенный поиск

Оптимизация комбинированной антигипертензивной терапии при резистентной артериальной гипертензии

https://doi.org/10.18705/1607-419X-2011-17-4-384-390

Полный текст:

Аннотация

В статье рассматривается проблема лечения пациентов с резистентной артериальной гипертензией, представлены современные подходы к подбору комбинированной терапии, использованию рациональных комбинаций препаратов.

Об авторах

И. В. Емельянов
ФГБУ «Федеральный Центр сердца, крови и эндокринологии имени В.А. Алмазова» Минздравсоцразвития РФ, Санкт-Петербург
Россия


А. О. Конради
ФГБУ «Федеральный Центр сердца, крови и эндокринологии имени В.А. Алмазова» Минздравсоцразвития РФ, Санкт-Петербург
Россия


Список литературы

1. Rayner M., Petersen S. European cardiovascular disease statistics. British Heart Foundation: London. - Available from: <http://www.heartstats.org/homepage.asp> [accessed on 12 February 2008].

2.

3. Egan B.M., Zhao Y., Axon R.N. US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008 // J. Am. Med. Assoc. - 2010. - Vol. 303, № 20. - P. 2043-2050.

4.

5. Colhoun D.A., Jones <http://circ.ahajournals.org/search?author1=Daniel+Jones&sortspec=date&submit=Submit> D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Circulation. - 2008. - Vol. 117, № 25. - P. e510-e526.

6.

7. Шальнова С.А. Проблемы лечения артериальной гипертонии // Кардиоваск. терапия и профилакт. - 2003. - № 3. - C. 17-21.

8.

9. Garg J.P., Elliott W.J., Folker A., Izhar M., Black H.R. RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts // Am. J. Hypertens. - 2005. - Vol. 18, № 5, Pt. 1. - P 619-626.

10.

11. Cushman W.C., Ford C.E., Cutler J.A. et al., for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American Settings: the antihypertensive and lipid-lowering and treatment to prevent heart attack trial (ALLHAT) // J. Clin. Hypertens. - 2002. - Vol. 4, № 6. - P. 393-404.

12.

13. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. - 2009. - Vol. 27, № 11. - P. 2121-2158.

14.

15. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25, № 6. - P. 1105-1187.

16.

17. Staessen J.A., Fagard R., Thijs L. et al., for the Systolic Hypertension in Europe Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension // Lancet. - 1997. - Vol. 350, № 9080. - P. 757 - 764.

18.

19. Liu L., Wang J.L., Gong L., Liu G., Staessen J.A. For the Syst-China Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension // J. Hypertens. - 1998. - Vol. 16, № 12, Pt. 1. - P. 1823-1829.

20.

21. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Principal results of Hypertension Optimal Treatment (HOT) randomized trial // Lancet. - 1998. - Vol. 351, № 9118. - P. 1755-1762.

22.

23. Dahlof D., Sever P.S., Poulter N.R. et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial <http://www.ncbi.nlm.nih.gov/pubmed/16154016> // Lancet. - 2005. - Vol. 366, № 9489. - P. 895-906.

24.

25. Czernichow S., Zanchetti A., Turnbull F. et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials // J. Hypertens. - 2011. - Vol. 29, № 1. - P. 4-16.

26.

27. Jameson K., Weber M.A., Bakris G.L. et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. - 2008. - Vol. 359, № 23. - P. 2417-2428.

28.

29. Марцевич С.Ю., Кутишенко Н.П., Деев А.В., Алимова Е.В., Семенова Ю.Э. Изучение терапевтической эквивалентности двух препаратов амлодипина (оригинального и воспроизведенного) у больных артериальной гипертонией. Результаты двойного слепого рандомизированного перекрестного исследования // Рос. кардиол. журн. - 2004. - Т. 48, № 4. - С. 53-56.

30.

31. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) // Lancet. - 2000. - Vol. 356, № 9227. - P. 366-372.

32.

33. Kolloch R.E. INVEST: Results of combined strategies to control blood pressure // Clin. Cardiol. - 2001. - Vol. 24, Suppl. V. - P. V12-V13.

34.

35. Hall J.E., Guyton A.C., Smith M.J. Jr, Coleman T.G. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin // Am. J. Physiol. - 1980. -Vol. 239, № 3. - P. F271-F280.

36.

37. Hall J.E. Control of sodium excretion by angiotensin: intrarenal mechanisms and blood pressure regulation // Am. J. Physiol. - 1986. - Vol. 250, № 6, Pt. 2. - P. R960-R972.

38.

39. Hall J.E., Brands M.W., Shek E.W. Central role of the kidney and abnormal fluid volume control in hypertension // J. Hum. Hypertens. - 1996. - Vol. 10, № 10. - P. 633-639.

40.

41. Hall J.E., Crook E.D., Jones D.W., Wofford M.R., Dubbert P.M. Mechanisms of obesity-associated cardiovascular and renal disease // Am. J. Med. Sci. - 2002. - Vol. 324, № 3. - P. 127-137.

42.

43. Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators // N. Engl. J. Med. - 2000. - Vol. 342, № 3. - P. 145-153.

44.

45. Lonn E.M., Yusuf S., Dzavik V. et al. Effects of Ramipril and Vitamin E on Atherosclerosis The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) // Circulation. - 2001. - Vol. 103, № 7. - P. 919-925.

46.

47. Furberg C.D., Psaty B.M. Should evidence-based proof of drug efficacy be extrapolated to a «class of agents»? // Circulation. - 2003. - Vol. 108, № 21. - P. 2608-2610.

48.

49. Марцевич С.Ю., Лукина Ю.В., Дмитриева Н.А. и др. Сравнение нового дженерика и оригинального препарата рамиприла у больных артериальной гипертонией и высоким риском сердечно-сосудистых осложнений // Рацион. фармакотер. кард. - 2010. - Т. 6, № 1. - С. 20-28.

50.

51. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // Br. Med. J. - 2009. - Vol. 338. - P. b1665.

52.

53. Sanford M., Keam S.J. Olmesartan modoximil/amlodipine // Drugs. - 2009. - Vol. 69, № 6. - P. 717-729.

54.

55. Poldermans D., Glazer R., Karagiannis G. et al. Tolerability and blood pressure lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension // Clin. Ther. - 2007. - Vol. 29. - P. 279-289.

56.

57. Alleman Y., Fraile B., Lambert M. et al. Efficacy of the combination of amlodipine and valsartan in patients uncontrolled with monotherapy: the Exforge in Failure after Single Therapy (Ex-FAST) Study // J. Clin. Hypertens. (Greenwich). - 2008. - Vol. 10, № 3. - P. 185-194.

58.

59. Hirsch S. A different approach to resistant hypertension // Cleveland Clin. J. Med. - 2007. - Vol. 74, № 6. - P. 449-455.

60.

61. Gifford R., Tarazi R. Resistant hypertension: diagnosis and management // Ann. Intern. Med. - 1978. - Vol. 88, № 5. - P. 661-665.

62.

63. Ramsey L.E., Silas J.E., Freestone S. Diuretic treatment of resistant hypertension // Br. Med. J. - 1980. - Vol. 281, № 6248. - P. 1101-1103.

64.

65. Graves G.W., Bloomfield R.L., Bukalew V.M. Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy // Am. J. Med. Sci. - 1989. - Vol. 298, № 6. - P. 361-365.

66.

67. Taler S.J., Textor S.C., Augustine J.E. Resistant hypertension: comparing hemodynamic management to specialist care // Hypertension. - 2002. - Vol. 39, № 5. - P. 982-988.

68.

69. Materson B.J., Reda D.J., Cushman W.C., Henderson W.G. Results of combination anti-hypertensive therapy after failure of each of the components. Department of veterans affairs cooperative study group on antihypertensive agents // J. Hum. Hypertens. - 1995. - Vol. 9, № 10. - P. 791-796.

70.

71. Moser M. Suppositions and speculations - their possible effects on treatment decisions in the management of hypertension // Am. Heart. J. - 1989. - Vol. 118, № 6. - P. 1362-1369.

72.

73. McInnes G.T., Yeo W.W., Ramsay L.E., Moser M. Cardiotoxicity and diuretics: much speculation, little substance // J. Hypertens. - 1992. - Vol. 10, № 4. - P. 317-335.

74.

75. Freis E.D. The efficacy and safety of diuretics in treating hypertension // Ann. Intern. Med. - 1995. - Vol. 122, № 3. - P.223-226.

76.

77. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP) // J. Am. Med. Assoc. - 1991. - Vol. 265, № 24. - P. 3255-3264.

78.

79. Чазова И.Е., Мартынюк Т.В., Небиеридзе Д.В. и др. Сравнительная эффективность лечения фиксированными комбинациями различных доз рамиприла и гидрохлоротиазида // Кардиоваск. терапия и профилакт. - 2010. - Т. 9, № 4. - С. 25-31.

80.

81. Moser M., Setaro J. Resistant or difficult-to-control hypertension // N. Engl. J. Med. - 2006. - Vol. 355, № 4. - P. 385-392.

82.

83. Calhoun D.A., Nishizaka M.K., Zaman M.A., Thakkar R.B., Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension // Hypertension. - 2002. - Vol. 40, № 6. - P. 892-896.

84.

85. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension // Am. J. Hypertens. - 2003. - Vol. 16, № 11, Pt. 1. - P. 925 - 930.

86.

87. Parthasarathy K.H., Alhashmi K., McMahon A.D. Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study // BMC Cardiovasc. Disorders. - 2007. - Vol. 7. - P. 14.

88.

89. Chapman N., Dobson J., Wilson S. et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension // Hypertension. - 2007. - Vol. 49, № 4. - P. 839-845.

90.

91. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension // Hypertension. - 2010. - Vol. 55, № 1. - P. 147-152.

92.

93. Sharabi Y., Adler E., Shamis A., Nussinovitch N., Markovitz A., Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension // Am. J. Hypertens. - 2006. - Vol. 19, № 7. - P. 750-755.

94.

95. Lane D.A., Shah S., Beevers D.G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. // J. Hypertens. - 2007. - Vol. 25, № 4. - P. 891-894.

96.

97. Vбclavнk <http://hyper.ahajournals.org/search?author1=Jan+V%C3%A1clav%C3%ADk&sortspec=date&submit=Submit> J. Sedlбk <http://hyper.ahajournals.org/search?author1=Richard+Sedl%C3%A1k&sortspec=date&submit=Submit> R., Plachэ <http://hyper.ahajournals.org/search?author1=Martin+Plach%C3%BD&sortspec=date&submit=Submit> M. et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT), a randomized, double-blind, placebo-controlled trial // Hypertension. - 2011. - Vol. 57, № 6. - P. 1069-1075.

98.

99. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., Lilledahl N.P. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment // J. Hypertens. - 2004. - Vol. 22, № 11. - P. 2217-2226.

100.

101. Saha C., Eckert G.J., Ambrosius W.T. et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension // Hypertension. - 2005. - Vol. 46, № 3. - P. 481-487.

102.

103. Sarafidis P., Bakris G.L. Resistant hypertension. An overview of evaluation and treatment // J. Am. Coll. Cardiol. - 2008. - Vol. 52, № 22. - P. 1749-1757.

104.

105. Bangalore S., Parkar S., Grossman E., Messerli F.H. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus // Am. J. Cardiol. - 2007. - Vol. 100, № 8. - P. 1254-1262.

106.

107. Bakris <http://hyper.ahajournals.org/search?author1=George+L.+Bakris&sortspec=date&submit=Submit> G.L, Lindholm L.H., Black <http://hyper.ahajournals.org/search?author1=Henry+R.+Black&sortspec=date&submit=Submit> H.L. et al. Divergent results using clinic and ambulatory blood pressures report of a Darusentan-Resistant Hypertension Trial // Hypertension. - 2010. - Vol. 56, № 5. - P. 824-830.

108.

109. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months // Hypertension. - 2011. - Vol. 57, № 5. - P. 911-917.

110.

111. Bisognano J.D., Bakris G., Nadim M.K. et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial // J. Am. Coll. Cardiol. - 2011. - Vol. 58, № 7. - P. 765-773.

112.


Для цитирования:


Емельянов И.В., Конради А.О. Оптимизация комбинированной антигипертензивной терапии при резистентной артериальной гипертензии. Артериальная гипертензия. 2011;17(4):384-390. https://doi.org/10.18705/1607-419X-2011-17-4-384-390

For citation:


Emelianov I.V., Konradi A.O. Rational combination therapy in resistant arterial hypertension. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(4):384-390. (In Russ.) https://doi.org/10.18705/1607-419X-2011-17-4-384-390

Просмотров: 45


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)